- abnormal small intestine morphology / MGI
- thick pulmonary interalveolar septum / MGI
- edema / MGI
- skin edema / MGI
- abnormal lymphatic vessel morphology / MGI
- hemorrhage / MGI
- respiratory failure / MGI
- postnatal lethality / MGI
- no abnormal phenotype detected / MGI
- small heart / MGI
- abnormal pulmonary alveolus morphology / MGI
- abnormal heart atrium morphology / MGI
- abnormal vascular branching morphogenesis / MGI
- intestinal edema / MGI
- abnormal vascular endothelial cell development / MGI
- abnormal lymph circulation / MGI
- pulmonary edema / MGI
- abnormal endocardium morphology / MGI
- lymphatic vessel hyperplasia / MGI
- dilated vasculature / MGI
- abnormal renal glomerulus morphology / MGI
- cardiovascular system phenotype / MGI
- abnormal vascular endothelial cell morphology / MGI
- abnormal lymphangiogenesis / MGI
- neonatal lethality, complete penetrance / MGI
- perinatal lethality, complete penetrance / MGI
- lethality throughout fetal growth and development, complete penetrance / MGI
- prenatal lethality, incomplete penetrance / MGI
- embryonic lethality during organogenesis, incomplete penetrance / MGI
C57BL/6J-Tie1em1Kaali/Oulu
| Status | Available to order |
| EMMA ID | EM:15969 |
| Citation information | RRID:IMSR_EM:15969 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | C57BL/6J-Tie1em1Kaali/Oulu |
| Alternative name | Tie1R979W (Tie1-RW) |
| Strain type | Endonuclease-mediated |
| Allele/Transgene symbol | Tie1em-R979W |
| Gene/Transgene symbol | Tie1 |
Information from provider
| Provider | Kari Alitalo |
| Provider affiliation | Wihuri Research Institute |
| Genetic information | Using the CRISPR/Cas9 technique, four point mutations were generated in exon 18 of the Tie1 gene. Two of the mutations were intended to cause an amino acid substitution at codon 979, changing arginine (Arg) to tryptophan (Trp). The other two mutations were silent with respect to the encoded amino acid residues. These additional mutations were required to prevent the RNP complex from targeting the already modified genomic DNA and to create a new restriction enzyme cutting site, which was utilized for genotyping. Changes in exon 18: Codon 978 (silent mutation): GCC (Ala) → GCA (Ala) → no amino acid change Codon 979 (knock-in mutation): CGA (Arg) → TGG (Trp) → amino acid change Codon 980 (silent mutation): AAT (Asn) → AAC (Asn) → no amino acid change CRISPR technology details: The Alt-R™ S.p. HiFi Cas9 Nuclease V3 was obtained from Integrated DNA Technologies. The Cas9 gene was not inserted into the mouse genome. |
| Phenotypic information | Homozygous:Mice homozygous for the mutation die soon after birth. As early as embryonic day 15.5, the homozygous embryos show pronounced nuchal translucency. At E18.5, the embryos are alive but are swollen and exhibit hemorrhage at the tip of the tail and sometimes in other parts of the skin. The embryos display hypoplastic lymphatic vessels, immature collecting vessels, and a lack of valves in the dorsal skin, mesentery, and intestine.Heterozygous:Mice heterozygous for the mutation do not display any obvious phenotype. |
| Breeding history | Microinjected embryos of C57BL/6J origin were transferred into pseudopregnant females, and pups positive for the knock-in allele were backcrossed to the C57BL/6J strain. The F1 generation was further backcrossed to the C57BL/6J strain eight times. |
| References |
|
| Homozygous fertile | no |
| Homozygous viable | no |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | University of Oulu, Oulu, Finland |
Disease and phenotype information
MGI phenotypes (gene matching)
Literature references
- Loss-of-function mutations of the TIE1 receptor tyrosine kinase cause late-onset primary lymphedema.;Brouillard Pascal, Murtomäki Aino, Leppänen Veli-Matti, Hyytiäinen Marko, Mestre Sandrine, Potier Lucas, Boon Laurence M, Revencu Nicole, Greene Arin, Anisimov Andrey, Salo Miia H, Hinttala Reetta, Eklund Lauri, Quéré Isabelle, Alitalo Kari, Vikkula Miikka, ;2024;The Journal of clinical investigation;134;; 38820174
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).
